Nano-X Imaging

Rising Regulatory Hurdles Will Test Digital Imaging But Allow Revival

AnalystLowTarget

Not Invested

Community Contributor

Published

24 Aug 25

Updated

12 Dec 25

Views

n/a

AnalystLowTarget's Fair Value

n/a

-55.7%

-9.5%

-55.7%

-9.5%

You can edit this narrative until Dec 13 3:10 AM. Then, changes will post as Updates.

Author's Valuation

US$753.7% undervalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on 12 Dec 25

Fair value Increased 17%

NNOX Will Benefit From Expanding AI Imaging Partnerships And Growing Global Deployments

Analysts have raised their price target on Nano-X Imaging by approximately 17 percent to reflect stronger projected revenue growth and modestly improved long term profitability, which is partially offset by a slightly higher discount rate and a lower assumed future price to earnings multiple. What's in the News Nano-X Imaging completed a registered direct follow on equity offering of approximately $15 million, issuing 3,826,530 ordinary shares at $3.92 per share to support growth initiatives (company filing).

AnalystLowTarget Fair Value

US$7

53.7% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

53.98%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.52%

Calculation

US$3.93m

Earnings '28

159.24x

PE Ratio '28

US$626.15m

Market Cap '28

US$626.15m

Market Cap '28

70.50m

No. shares '28

US$8.88

Share Price '28

US$8.88 Share Price '28

Discounted to 2025 @ 8.52% p.a.

US$6.95

Fair Value '25